Haemonetics Corporation
HAE
Classement en actions
#3280
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Prix de l'action
$118.48
Capitalisation boursière
$5.39B
Changement (1 jour)
-0.02%
Changement (1 an)
133.64%
Pays
US
Échange Haemonetics Corporation (HAE)
Catégorie
Healthcare
Bénéfices pour Haemonetics Corporation (HAE)
Bénéfices en Jun 2026 TTM : $130.44M
Selon les derniers rapports financiers de Haemonetics Corporation, les bénéfices actuels de l'entreprise sont de $130.44M. En 2024, l'entreprise a réalisé un bénéfice de $151.87M, une augmentation par rapport à celui de 2023 qui était de $141.40M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Haemonetics Corporation de 2000 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $130.44M | -38.49% |
| 2025 | $212.07M | 39.64% |
| 2024 | $151.87M | 7.40% |
| 2023 | $141.40M | 122.23% |
| 2022 | $63.63M | -12.73% |
| 2021 | $72.91M | -16.34% |
| 2020 | $87.15M | 18.36% |
| 2019 | $73.63M | 23.48% |
| 2018 | $59.63M | -317.03% |
| 2017 | $-27.48M | -48.56% |
| 2016 | $-53.42M | -271.40% |
| 2015 | $31.17M | -14.38% |
| 2014 | $36.40M | -27.05% |
| 2013 | $49.90M | -44.25% |
| 2012 | $89.50M | -18.70% |
| 2011 | $110.08M | 35.45% |
| 2010 | $81.27M | -4.39% |
| 2009 | $85.00M | 9.96% |
| 2008 | $77.30M | 6.87% |
| 2007 | $72.34M | -32.32% |
| 2006 | $106.88M | 78.61% |
| 2005 | $59.84M | 30.62% |
| 2004 | $45.81M | 18.66% |
| 2003 | $38.61M | 0.26% |
| 2002 | $38.51M | 122.24% |
| 2001 | $17.33M | -36.59% |
| 2000 | $27.33M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $7.51B | 5,658.42% |
US
|
|
| $5.56B | 4,164.96% |
IE
|
|
| $5.15B | 3,846.79% |
US
|
|
| $3.86B | 2,860.10% |
US
|
|
| - | - |
DE
|
